The board of directors of China Shineway Pharmaceutical Group Limited announced that Ms. Wang Guihua (Ms. Wang) has been appointed as independent non-executive director of the Company with effect from 1 April 2023. Ms. Wang, aged 62, is a holder of undergraduate degree and a deputy chief pharmacist. She successively served in management positions in the science and technology department, production department and international cooperation department of China Traditional Chinese Medicine Co. Ltd. (formerly known as Chinese Medicine Company) from August 1983 to October 2000, served as the PRC general manager of Thailand Orient Pharmaceutical Co. Ltd. from September 1996 to October 1998; the deputy general manager and chairman of the labor union of Huahe Pharmaceutical Co. Ltd. from October 2000 to August 2005; an independent director of Shandong Wohua Pharmaceutical Technology Co. Ltd. from June 2014 to February 2019; a director of Wohua Pharmaceutical from February 2019 to February 2022; an independent director of Hunan Fangsheng Pharmaceutical Co. Ltd. from June 2015 to April 2017; an independent director of Chongqing Huasen Pharmaceutical Co. Ltd. from September 2015 to September 2021; an independent director of Guangdong Taiantang Pharmaceutical Co. Ltd. from May 2016 to January 2023; an
independent director of Henan Lingrui Pharmaceutical Co. Ltd. from March 2016 to March 2019; an independent director of Inner Mongolia Furui Medical Technology Co. Ltd. from April 2016 to April 2019, and has served as the secretary general of the China Association of Traditional Chinese Medicine/National Technical Committee of Standardization of Traditional Chinese Medicine since August 2005; an independent director of Hainan Huluwa Pharmaceutical Group Co. Ltd. and an independent director of Sailing Pharmaceutical Technology Group Co. Ltd. since June 2021. The Board announced that with effect from 1 April 2023, Ms. Cheng Li (Ms. Cheng) will cease to serve as an independent non-executive Director in order to devote more time to pursue her personal interests. Ms. Cheng has confirmed that she has no disagreement with the Board and that she is not aware of any matters in relation to her cessation as an independent non-executive Director need to be brought to the attention of the shareholders of the Company. The Board announced that following the above changes, with effect from 1 April 2023: Ms. Wang has been appointed as the chairman of the Remuneration Committee of the Company and a member of the Audit Committee and the Corporate Social Responsibility and Sustainability Committee of the Company; and Ms. Cheng has ceased to act as the chairman of the Remuneration Committee of the Company and a member of the Audit Committee and the Corporate Social Responsibility and Sustainability Committee of the Company.